Navigation Links
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Date:12/8/2008

h chronic hepatitis C. Hepatitis C virus can cause serious liver disease, leading to cirrhosis, primary liver cancer and even death.

Conference Call

HGS management will hold a conference call to discuss this announcement today at 8:15 AM Eastern. Investors may listen to the call by dialing 888-215-6982 or 913-312-0389, passcode 7154642, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203-1112 or 719- 457-0820, confirmation code 7154642. Today's conference call also will be webcast and can be accessed at www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins to download any software required. Both the audio replay and the archive of the conference call webcast will remain available for several days.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is awaiting authorization to begin the delivery of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. HGS also has three drugs in clinical development for the treatment o
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , July 3, 2015 ... voivat hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Open Innovation in Science" -jatkokoulutusohjelmaan ... Boltzmann Gesellschaftin (LBG) tekemän, kansainvälisiä ... mukaan terveystieteiden kaksi suurinta haastetta ...
(Date:7/3/2015)... 3, 2015 Forskare ... 2015 på  http://www.openinnovationinscience.at till det återkommande ... som hålls i Wien ... med internationella forskare och vetenskapsmän som genomfördes ... två största utmaningar bristen på incitament för ...
(Date:7/3/2015)... , July 3, 2015 ... den 22. september 2015 på  http://www.openinnovationinscience.at ... Science", der finder sted i ... nylig undersøgelse af internationale forskere og videnskabsmænd ... de to største udfordringer for sundhedsvidenskaben manglen ...
(Date:7/2/2015)... -- Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property development ... property, today announced a litigation update. In ... Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, in the ... Virginia , the Court issued a ... claims in favor of the Defendants on the one ...
Breaking Biology Technology:Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3
... More than a third,of the people who ... about the,company,s prescription savings programs learned of the ... year-long survey of more than 12,000,patients., The ... who called,AstraZeneca,s information center regarding prescription savings programs,said ...
... Solid Financial Performance While Building for the Future, ... ) today reported strong sales and profit growth in ... and clinical,programs., Revenue increased 25 percent to approximately ... The increase was driven by,growth across all areas of ...
... the past two decades,stem cell transplantation has evolved ... a viable option for patients with hematologic (blood),malignancies ... the Adult Blood and Marrow Stem Cell Transplantation ... Center are,responsible for many of the innovations and ...
Cached Biology Technology:AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 2AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 3Genzyme Reports Strong Second-Quarter Growth 2Genzyme Reports Strong Second-Quarter Growth 3Genzyme Reports Strong Second-Quarter Growth 4Genzyme Reports Strong Second-Quarter Growth 5Genzyme Reports Strong Second-Quarter Growth 6Genzyme Reports Strong Second-Quarter Growth 7Genzyme Reports Strong Second-Quarter Growth 8Genzyme Reports Strong Second-Quarter Growth 9Genzyme Reports Strong Second-Quarter Growth 10Genzyme Reports Strong Second-Quarter Growth 11Genzyme Reports Strong Second-Quarter Growth 12Genzyme Reports Strong Second-Quarter Growth 13Genzyme Reports Strong Second-Quarter Growth 14Genzyme Reports Strong Second-Quarter Growth 15Genzyme Reports Strong Second-Quarter Growth 16Genzyme Reports Strong Second-Quarter Growth 17Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants 2Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants 3Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants 4
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/17/2015)... Germany , June 17, 2015 ... today launched new Investigator ® STR assay kits for ... the United States . The new genetic fingerprint kits ... markers (short tandem repeats or STRs) for DNA matching. They ... quality of DNA in each sample, a novel QIAGEN technology ...
(Date:6/17/2015)... GARDENS, Fla. , June 17, 2015 /PRNewswire/ ... solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... casual sandwich chain, to increase security, improve accountability ... fingerprint readers enable instant, non-repudiable identity confirmation for ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... Virginia Tech biologist proposes to use a physics strategy called ... where they will be sensitive to antibiotics. In medicine, ... she thumps your chest. In physics, resonance is a periodic ... of a natural system,s frequency. Sound waves are an example ...
... study identifies cattle feed as a possible culprit in ... a moderately-populated agricultural region has higher levels ... than many densely-populated cities. The report, which explains how ... ozone, is in ACS, Environmental Science & Technology ...
... in green tea renowned for their powerful antioxidant ... the eye. Their new report, the first documenting how ... substances, raises the possibility that green tea may protect ... in ACS, bi-weekly Journal of Agricultural and Food ...
Cached Biology News:Physics strategy tested as solution for antibiotic resistance 2
Request Info...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
... Timp-4 has been reported in ... some fibroblasts in cell culture conditions. ... ester TPA stimulates production of TIMP-4 ... low protein levels produced often require ...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Biology Products: